Last reviewed · How we verify
rPA vaccine containing alhydrogel
rPA vaccine containing alhydrogel is a Biologic drug developed by PharmAthene UK Limited. It is currently in Phase 2 development.
At a glance
| Generic name | rPA vaccine containing alhydrogel |
|---|---|
| Sponsor | PharmAthene UK Limited |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase II Study of Range and Schedule of rPA Doses (PHASE2)
- Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rPA vaccine containing alhydrogel CI brief — competitive landscape report
- rPA vaccine containing alhydrogel updates RSS · CI watch RSS
- PharmAthene UK Limited portfolio CI
Frequently asked questions about rPA vaccine containing alhydrogel
What is rPA vaccine containing alhydrogel?
rPA vaccine containing alhydrogel is a Biologic drug developed by PharmAthene UK Limited.
Who makes rPA vaccine containing alhydrogel?
rPA vaccine containing alhydrogel is developed by PharmAthene UK Limited (see full PharmAthene UK Limited pipeline at /company/pharmathene-uk-limited).
What development phase is rPA vaccine containing alhydrogel in?
rPA vaccine containing alhydrogel is in Phase 2.